IceCure Medical Ltd. (NASDAQ:ICCM)
| Market Cap | $1.80M-96.3% |
| Revenue (ttm) | $3.92M+31.8% |
| Net Income | -$17.24M-12.8% |
| EPS | -$5.71+26.9% |
| Shares Out | 2.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 202,665 |
| Open | $0.91 |
| Previous Close | $1.00 |
| Day's Range | $0.77 - $0.91 |
| 52-Week Range | $0.65 - $22.20 |
| Beta | 0.43 |
| Analysts | Buy |
| Price Target | $1.00(+24.91%) |
| Earnings Date | Mar 16, 2027 |
About ICCM
Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.
Next catalysts
- Mar 16, 2027Earnings report
$ICCM stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ICCM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ICCM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ICCM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ICCM Revenue by Segment or Geography
Source: SEC EDGAR (10-Q/10-K)
U.S. Patents
New ICCM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ICCM from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from ICCM’s recent data — informational, not investment advice
What’s Behind the Score
News check: Strong YoY sales growth and geographic expansion offset Q3 loss and revenue miss; new patent grants add IP strength.
